- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00249769
Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Japanese encephalitis is the leading cause of viral neurological disease and disability in Asia. The severity of sequelae, together with the volume of cases, make JE the most important cause of viral encephalitis in the world. Approximately 3 billion people-including 700 million children-live in Asian areas at risk for JE. JE most commonly infects children between the ages of 1 and 15 years, and can also infect adults in areas where the virus is newly introduced. More than 50,000 cases are reported annually and cause an estimated 10,000 to 15,000 deaths. This figure is believed to represent only a small proportion of the disease burden that actually exists.
An effective vaccine has existed since 1941, but has not reached the poorest countries in Asia. During the 60 years that the vaccine has been available, JE has infected an estimated 10.5 million children, resulting in more than 3 million deaths and more than 4 million children living with long-term disabilities. Control of this disease has been limited due to poor disease surveillance, a limited and unstable vaccine supply, lack of guidance and programmatic support for immunization, and limited advocacy.
A successful vaccine should be safe, efficacious, affordable, administered in a single dose, and easily incorporated into the routine Expanded Programmes on Immunization (EPI) programs. This study will help ensure the safety of SA 14-14-2 simultaneously administered with measles vaccine, paving the way for its use in routine EPI programs. If this candidate becomes widely available, it will drastically increase the feasibility of routine JE immunization in Asia, reducing the devastating death and disability caused by this disease. In addition to impacting low-income countries, the vaccine will allow countries that purchase vaccine-such as Thailand, Vietnam, Sri Lanka, and India-to recover health care dollars, improve their present programs, and address other unmet health care needs.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Manila, Philippines
- Research Institute for Tropical Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is healthy, aged between 8 months (± 2 weeks) at inclusion visit
- Subject is a full-term infant
- Subject's parents or legal guardian willing to provide signed informed consent.
- Children have completed 3 doses each of diphtheria, tetanus, pertussis (DTP) and oral polio vaccine (OPV).
Exclusion Criteria:
- History of documented HIV.
- Known or suspected impairment of immunologic function.
- History of serious chronic disease
- Underlying medical condition such as inborn errors of metabolism, failure to thrive, bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or chronic treatment.
- Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5°C at the time of inclusion.
- History of documented suspected encephalitis, encephalopathy, or meningitis
- History of measles
- History of thrombocytopenic purpura.
- Received any JE or measles vaccine prior to enrollment.
- Received any vaccine, other than the study vaccines, within 2 weeks prior to or scheduled to receive a non-study vaccination during the conduct of this trial.
- Hypotonic - hyporesponsiveness, after the preceding vaccination.
- History of seizures, including history of febrile seizures, or any other neurologic disorder.
- Prior or anticipated receipt of immune globulin or other blood products, or injected or oral corticosteroids or other immune modulator therapy except routine vaccines within 6 weeks of administration of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting <7 days may be included in the trial as long as they have not received more than one course within the last 2 weeks prior to enrollment.
- Suspected or known hypersensitivity to any of the investigational or marketed vaccine components.
- Serious adverse event related to the vaccine (i.e., possible, probably, definite)
- Persistent inconsolable crying (>3 hours) observed after a previous dose.
- Unable to attend the scheduled visits or comply with the study procedures.
- Enrolled in another clinical trial involving any therapy.
- Any condition that in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the study objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LJEV then MV
Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.
|
Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake.
After reconstitution, it turns into a transparent orange red liquid.
Its container is a vial.
It is stored and transported between 2°C to 8°C and protected from light.
Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus.
The 0.5ml injection is delivered subcutaneously via auto-disable syringe.
Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO). SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979. |
EXPERIMENTAL: LJEV and MV
Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.
|
Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake.
After reconstitution, it turns into a transparent orange red liquid.
Its container is a vial.
It is stored and transported between 2°C to 8°C and protected from light.
Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus.
The 0.5ml injection is delivered subcutaneously via auto-disable syringe.
Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO). SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979. |
EXPERIMENTAL: MV then LJEV
Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.
|
Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake.
After reconstitution, it turns into a transparent orange red liquid.
Its container is a vial.
It is stored and transported between 2°C to 8°C and protected from light.
Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus.
The 0.5ml injection is delivered subcutaneously via auto-disable syringe.
Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO). SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination
Time Frame: Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)
|
Seroprotection after measles vaccination was defined as a measles antibody titer ≥ 120 mIU/mL.
Measles immunoglobulin G (IgG) antibody was determined using the Enzygnost® Anti-Measles Virus/IgG enzyme-linked immunosorbent assay(ELISA) assay from Siemens, Marburg, Germany.
|
Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Seroprotection for Japanese Encephalitis 4 Weeks After Vaccination
Time Frame: Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)
|
Seroprotection after LJEV was defined as at least 1:10 dilution as recommended by the World Health Organization (WHO).
JE antibody titers were determined by a plaque reduction neutralization test (PRNT).
|
Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)
|
Geometric Mean Concentration (GMC) of Measles Antibodies After Vaccination
Time Frame: Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)
|
Measured using the Enzygnost® Anti-Measles Virus/IgG ELISA assay from Siemens, Marburg, Germany.
|
Day 0 (before vaccination) and Day 28 (4 weeks after measles vaccination)
|
Geometric Mean Titer (GMT) of Japanese Encephalitis Antibodies After Vaccination
Time Frame: Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)
|
Assayed by plaque reduction neutralization test (PRNT).
|
Day 0 (before vaccination) and Day 28 (4 weeks after LJEV vaccination)
|
Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Live Attenuated Japanese Encephalitis Vaccine (LJEV)
Time Frame: Up to 7 days after LJEV administration
|
Local reactions included erythema, pain, swelling, or induration.
Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, vomiting, or fever.
The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.
|
Up to 7 days after LJEV administration
|
Number of Participants Experiencing Local and Systemic Reactogenicity After Receiving Measles Vaccine
Time Frame: Up to 7 days after measles vaccination
|
Local reactions included erythema, pain, swelling, and induration.
Systemic reactions included loss of appetite, crying, diarrhea, drowsiness, insomnia, irritability, and vomiting.
The parents of the participants recorded all local reactions and systemic events on an individual safety diary form.
|
Up to 7 days after measles vaccination
|
Number of Participants Experiencing Unsolicited Adverse Events (AE)
Time Frame: Up to 7 days post-vaccination
|
Up to 7 days post-vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Salvacion Gatchalian, MD, Research Institute for Tropical Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Encephalitis, Japanese
- Encephalitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- JEV01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Encephalitis, Japanese B
-
Mahidol UniversityCompletedEncephalitis, Japanese BThailand
-
PATHCompletedEncephalitis, Japanese BPhilippines
-
Medical University of ViennaValneva Austria GmbHUnknownImmune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.Japanese Encephalitis VaccineAustria
-
Indian Institute of ScienceWellcome Trust; PATH; University of Liverpool; National Institute of Mental Health...CompletedJapanese Encephalitis | Japanese Encephalitis VaccineIndia
-
Sanofi Pasteur, a Sanofi CompanyCompletedJapanese Encephalitis | Japanese Encephalitis Virus DiseaseKorea, Republic of
-
Cancer Institute and Hospital, Chinese Academy...Active, not recruiting
-
Valneva Austria GmbHCompleted
-
Valneva Austria GmbHCompletedEncephalitisUnited States, Australia, Denmark, Germany, Sweden
-
National Institute of Hygiene and Epidemiology,...Ministry of Health, Vietnam; Ministry of Science and Technology, VietnamCompleted
-
National Institute of Hygiene and Epidemiology,...Ministry of Health, Vietnam; Ministry of Science and Technology, VietnamCompleted
Clinical Trials on Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)
-
PATHCompleted
-
PATHInternational Centre for Diarrhoeal Disease Research, BangladeshCompleted
-
PATHMahidol University; Ministry of Health of Sri Lanka; Quintiles SingaporeCompletedJapanese EncephalitisSri Lanka
-
Indian Institute of ScienceWellcome Trust; PATH; University of Liverpool; National Institute of Mental Health...CompletedJapanese Encephalitis | Japanese Encephalitis VaccineIndia
-
PATHCompletedEncephalitis, Japanese BPhilippines
-
PATHSyneos Health; Research Institute for Tropical Medicine; DF/Net Research, Inc.CompletedEncephalitis, Japanese | Measles | Rubella | MumpsPhilippines
-
Sanofi Pasteur, a Sanofi CompanyCompletedJapanese Encephalitis | EncephalitisThailand
-
Sanofi Pasteur, a Sanofi CompanyCompletedJapanese Encephalitis | Japanese Encephalitis Virus DiseaseKorea, Republic of
-
Cancer Institute and Hospital, Chinese Academy...Guangdong Center for Disease Prevention and ControlUnknown
-
Chulalongkorn UniversitySanofi Pasteur, a Sanofi CompanyCompleted